Biogen (BIIB) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue:: $2.7 billion, up 3% year-over-year.

Core Pharmaceutical Revenue:: $1.8 billion, up 4% year-over-year and 12% quarter-over-quarter.

Growth Portfolio Revenue:: Over $1 billion, up 24% year-over-year and 25% quarter-over-quarter.

SPINRAZA Revenue:: $402 million, up 2% year-over-year and 7% quarter-over-quarter.

LEQEMBI Revenue:: $184 million, up 15% year-over-year and 9% quarter-over-quarter.

SYFOVRE and Empaveli Revenue:: Combined $128 million since acquisition on May 14, contributing significantly to growth.

Free Cash Flow:: $408 million generated in Q2.

Non-GAAP Diluted EPS Guidance:: Updated range of $12 to $13 for 2026, reflecting dilution from Apellis acquisition.

2Strategic Updates and Business Highlights

Growth Portfolio Expansion:: The growth portfolio now exceeds the legacy MS portfolio, driven by SPINRAZA high-dose, LEQEMBI, and new products from the Apellis acquisition.

Acquisition of Apellis:: Integration is progressing well, with SYFOVRE and Empaveli expected to contribute to mid- to high-teens growth through at least 2028.

Pipeline Development:: Five registrational Phase 3 trials expected in the next year, including studies in lupus (SLE and CLE) and Dravet syndrome.

Early-Stage Pipeline Rebuilding:: Three INDs filed this year, with plans for six new programs, focusing on autoimmune diseases and early-stage development.

3Forward Guidance and Outlook

Revenue Guidance:: Total revenue guidance updated from a mid-single-digit percentage decrease to a mid-single-digit percentage increase for 2026.

Core Operating Expenses:: Expected to be between $2.65 billion and $2.7 billion in the second half of 2026.

Long-Term Growth:: Biogen aims to return to sustainable revenue growth, leveraging both the Apellis acquisition and a robust late-stage pipeline.

4Bad News, Challenges, or Points of Concern

VUMERITY Revenue Decline:: Revenue down 7% year-over-year, indicating potential market challenges.

Competitive Pressures:: The market for MS treatments is becoming increasingly crowded, impacting the performance of products like the BTK inhibitor BIIB091.

Integration Risks:: While the Apellis acquisition is progressing, there are inherent risks associated with integrating new products and teams.

Market Access Dynamics:: Uncertainty remains regarding Part D coverage for LEQEMBI, which could affect patient access and adoption rates.

5Notable Q&A Insights

SPINRAZA High-Dose Demand:: Initial demand for high-dose SPINRAZA is exceeding expectations, with positive feedback from patients and physicians.

Lupus Trials Expectations:: Biogen is confident in its lupus trials (TOPAZ-1 and TOPAZ-2) but acknowledges the challenges of high placebo responses in previous studies.

SYFOVRE Growth Strategy:: The team is focusing on improving patient education and addressing discontinuation rates post-injection to enhance growth.

Felzartamab Potential:: There is significant optimism around felzartamab's potential in AMR, with a strong unmet need and promising early data. Overall, Biogen's Q2 2026 results reflect a positive trajectory in revenue growth, driven by strategic acquisitions and a strong pipeline, despite facing competitive pressures and market access challenges.